Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 5.1
edited by manuelmenendez
on 2025/01/27 23:04
Change comment: There is no comment for this version
To version 23.1
edited by manuelmenendez
on 2025/01/29 18:46
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,9 +2,10 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= Neurodiagnoses =
5 += //A new tridimensional diagnostic framework for CNS diseases// =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 +We aim to create a structured, interpretable, and scalable diagnostic tool.
8 8  )))
9 9  )))
10 10  
... ... @@ -12,19 +12,69 @@
12 12  (((
13 13  (% class="col-xs-12 col-sm-8" %)
14 14  (((
15 -= What can I find here? =
16 += What is this about and what can I find here? =
16 16  
18 +== **Overview** ==
19 +
20 +The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
21 +
22 +* **Axis 1**: Etiology (genetic or other causes of diseases).
23 +* **Axis 2**: Molecular Markers (biomarkers).
24 +* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 +
26 +[[For instance, neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
27 +
28 +
29 +This methodology enables:
30 +
31 +* Greater precision in diagnosis.
32 +* Integration of incomplete datasets using AI-driven probabilistic modeling.
33 +* Stratification of patients for personalized treatment.
34 +
35 +== **The case of neurodegenerative diseases** ==
36 +
37 +There have been described these 3 diagnostic axes:
38 +
39 +* (((
40 +**Axis 1: Etiology**
41 +
42 +* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
43 +* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
44 +* //Tests//: Genetic testing, lifestyle, and cardiovascular screening.
45 +)))
46 +* (((
47 +**Axis 2: Molecular Markers**
48 +
49 +* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
50 +* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
51 +* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
52 +)))
53 +* (((
54 +**Axis 3: Neuroanatomoclinical**
55 +
56 +* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
57 +* //Examples//: Hippocampal atrophy correlating with memory deficits.
58 +* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
59 +)))
60 +
61 +== **Applications** ==
62 +
63 +This system enhances:
64 +
65 +* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
66 +* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
67 +
17 17  == Who has access? ==
18 18  
19 19  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
20 20  
21 -== How to Contribute: ==
72 +== How to Contribute ==
22 22  
23 23  * Access the `/docs` folder for guidelines.
24 24  * Use `/code` for the latest AI pipelines.
25 25  * Share feedback and ideas in the wiki discussion pages.
26 26  
27 -== Key Objectives: ==
78 +== Key Objectives ==
28 28  
29 29  * Develop interpretable AI models for diagnosis and progression tracking.
30 30  * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
... ... @@ -38,11 +38,14 @@
38 38  {{toc/}}
39 39  {{/box}}
40 40  
41 -== Main contents: ==
92 +== Main contents ==
42 42  
43 43  * `/docs`: Documentation and contribution guidelines.
44 44  * `/code`: Machine learning pipelines and scripts.
45 45  * `/data`: Sample datasets for testing.
46 46  * `/outputs`: Generated models, visualizations, and reports.
98 +* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]]
99 +* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]]
100 +* [[to-do-list>>to-do-list]]
47 47  )))
48 48  )))
tridimensional.png
Author
... ... @@ -1,0 +1,1 @@
1 +XWiki.manuelmenendez
Size
... ... @@ -1,0 +1,1 @@
1 +149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -No
1 +Yes
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,0 +1,1 @@
1 +Allow
Levels
... ... @@ -1,0 +1,1 @@
1 +view
Users
... ... @@ -1,0 +1,1 @@
1 +XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,0 +1,1 @@
1 +Allow
Groups
... ... @@ -1,0 +1,1 @@
1 +XWiki.XWikiAllGroup
Levels
... ... @@ -1,0 +1,1 @@
1 +view